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Abstract
Brucellosis is a highly contagious zoonosis and still a major human health problem in endemic areas of the world. Although
several diagnostic tools are available, most of them are difficult to implement especially in developing countries where
complex health facilities are limited. Taking advantage of the identical structure and composition of the Brucella spp. and
Yersinia enterocolitica O:9 O-polysaccharide, we explored the application of a recombinant Y. enterocolitica O:9-
polysaccharide-protein conjugate (OAg-AcrA) as a novel antigen for diagnosis of human brucellosis. We have developed
and validated an indirect immunoassay using OAg-AcrA coupled to magnetic beads. OAg-AcrA was produced and purified
with high yields in Y. enterocolitica O:9 cells co-expressing the oligosaccharyltransferase PglB and the protein acceptor AcrA
of Campylobacter jejuni without the need for culturing Brucella. Expression of PglB and AcrA in Y. enterocolitica resulted in
the transfer of the host O-polysaccharide from its lipid carrier to AcrA. To validate the assay and determine the cutoff values,
a receiver-operating characteristic analysis was performed using a panel of characterized serum samples obtained from
healthy individuals and patients of different clinical groups. Our results indicate that, using this assay, it is possible to detect
infection caused by the three main human brucellosis agents (B. abortus, B. melitensis and B. suis) and select different cutoff
points to adjust sensitivity and specificity levels as needed. A cutoff value of 13.20% gave a sensitivity of 100% and a
specificity of 98.57%, and a cutoff value of 16.15% resulted in a test sensitivity and specificity of 93.48% and 100%,
respectively. The high diagnostic accuracy, low cost, reduced assay time and simplicity of this new glycoconjugate-magnetic
beads assay makes it an attractive diagnostic tool for using not only in clinics and brucellosis reference laboratories but also
in locations with limited laboratory infrastructure and/or minimally trained community health workers.
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Introduction
Human brucellosis is one of the world’s most widespread
bacterial zoonoses and, over the past decade, new foci of the
disease have emerged. Every year, more than 500,000 new cases
are reported globally with annual incidence rates that varies widely
(from ,2 to .500 per 1,000,000 population) among different
regions [1]. The etiological agents of brucellosis are Gram-
negative bacteria of the genus Brucella. B. melitensis, B. abortus and B.
suis are the three main human brucellosis pathogens whose
preferred natural host animals are sheep and goats, cattle, and
swine, respectively. The infection is primarily transmitted by
consumption of unpasteurized dairy products, direct contact with
infected animals (slaughterhouse workers and veterinarians), and
handling of cultures and clinical specimens in clinical, research,
and production laboratories. Since brucellosis is an important
cause of veterinary morbidity and mortality, it causes important
economic losses in endemic regions. Additionally, the disease can
lead to serious complications in affected patients with an important
public health issue. In this regard, when evaluating the economic
impact of the disease, this should include not only the cost of
treatment and diagnosis, but also the cost in terms of disability-
adjusted life years [2,3].
The wide spectrum of clinical manifestations and lack of
pathognomonic symptoms make human brucellosis difficult to
clinically diagnose and distinguish from several febrile conditions
that often occur in the same areas; therefore, laboratory tests are
essential for diagnosing the disease. Even though isolation of
Brucella, mainly from blood, continues to be the gold standard
method for the diagnosis of brucellosis, it presents several
drawbacks. The slow growth of Brucella in primary cultures delays
diagnosis for several days and the sensitivity is often low ranging
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from 50 to 90% depending on the stage of the disease, previous use
of antibiotics, the clinical specimen, and the culture method
employed. Furthermore, culturing Brucella sp. is hazardous and not
all the laboratories have suitable culture facilities [2,4,5]. Hence,
when the disease cannot be confirmed by culture, serological tests
play a major role in the routine diagnosis of brucellosis.
Currently, the diagnostic methods most commonly used for
human serological testing are agglutination, complement fixation,
and enzyme immunoassay tests [4,5]. All these assays use as
antigen the whole bacteria or bacterial extracts containing high
concentrations of the smooth lipopolysaccharide (sLPS) since the
humoral immune response to smooth brucellae is dominated by
antibodies to the O-polysaccharide section of Brucella sLPS.
In a previous work, we have produced a recombinant
glycoconjugate consisting in the O-polysaccharide (OAg) fraction
of Yersinia enterocolitica O:9 LPS covalently linked to the carrier
protein AcrA derived from Campylobacter jejuni (herein after OAg-
AcrA) [6]. The glycoprotein OAg-AcrA was produced and
purified using an in vivo bacterial glycosylation system that is
based on the combination of the LPS biosynthesis pathway and
the N-glycosylation pathway of Campylobacter jejuni [7]. In this
system, several glycosyltransferases sequentially add the sugars
required for the synthesis of a heptasacharide to the lipid-carrier
undecaprenyl pyrophosphate at the cytoplasmic side of the inner
membrane. The lipid-linked oligosaccharide is flipped into the
periplasm and transferred to the proteins by the oligosaccharyl-
transferase (OTase) PglB. Because PglB has relaxed glycan
specificity, co-expression of C. jejuni AcrA and PglB in Yersinia
enterocolitica O:9 resulted in glycosylation of AcrA with the host
OAg, which is also assembled onto the undecaprenyl pyrophos-
phate lipid carrier by a dedicated biosynthetic machinery
consisting of a set of sugar modifying enzymes, glycosyltransfer-
ases, and membrane transporters [6]. This machinery is common
to Y. enterocolitica O:9 and B. abortus. Mass spectrometry analysis of
the resulting glycoprotein demonstrated the transfer to AcrA of a
homopolymer of N-formylperosamine identical to the structure of
Y. enterocolitica O:9 and B. abortus O-polysaccharide [6]. The
saccharide moiety, but not the carrier protein AcrA, was
recognized by monoclonal antibodies against Y. enterocolitica O:9
and B. abortus O-polysaccharides, as well as by bovine sera obtained
from animals infected with a virulent strain of B. abortus.
Furthermore, using OAg-AcrA as antigen we were able to clearly
differentiate B. abortus-infected from non-infected animals demon-
strating the potential of this glycoconjugate to develop new
diagnostic tools for brucellosis [6].
In the present work, we have developed and validated a
magnetic beads-based immunoassay using the recombinant O:9-
polysaccharide-protein conjugate OAg-AcrA as a novel antigen for
the diagnosis of human brucellosis.
Materials and Methods
Ethics statement
In this study, we have analyzed a previously characterized sera
collection provided by the Brucellosis Division from the Hospital
de Enfermedades Infecciosas Francisco Javier Mun˜iz (Buenos
Aires, Argentina). These samples were obtained from patients who
were admitted to the hospital between the years 2008–2011 and
the data were analyzed anonymously. Blood donors’ samples were
obtained under informed consent and provided by Fundacio´n
Hemocentro Buenos Aires (Buenos Aires, Argentina).
Production and purification of the O:9-polysaccharide-
protein conjugate (OAg-AcrA)
Production and purification of the OAg-AcrA glycoconjugate
was performed as previously described [6]. Yersinia enterocolitica O:9
wild type strain transformed with the plasmids pMAF10 (encoding
the Campylobacter jejuni OTase PglB) and pMH5 (encoding the C.
jejuni carrier protein AcrA fused to an histidine tag) was grown
overnight at 37uC. Cultures were re-inoculated at 1/100 dilution
into fresh LB media and grown at 37uC for 2.5 h (OD600,0.5)
and PglBCj expression was induced with addition of arabinose to a
final concentration of 0.2% (w/v). Four hours after induction at
37uC, PglBCj was re-induced by a second addition of arabinose to
maximize glycosylation of AcrA. Cells were harvested by
centrifugation after a 20 h induction period and periplasmic
extracts were prepared by lysozyme treatment as described
elsewhere [7]. Subsequently, the periplasmic fraction was equil-
ibrated with 1/9 vol 106loading buffer (0.1 M imidazole, 3 M
NaCl, 0.2 M Tris-HCl pH 8.0) and subjected to Ni2+ affinity
chromatography. The column was equilibrated with 10 column
volumes of 16 loading buffer and loaded on a HisTrap HP
column (Amersham Pharmacia Biosciences) at a flow rate of 1 ml/
min. The column was washed with 25 column volumes of wash
buffer (0.02 M imidazole, 0.3 M NaCl, 0.02 M Tris-HCl pH 8.0),
and eluted from the column with the elution buffer (0.25 M
imidazole, 0.3 M NaCl, 0.02 M Tris-HCl pH 8.0).
Glycoconjugate magnetic beads-based immunoassay
development and optimization
Superparamagnetic COOH-modified microbeads (Bangs Lab-
oratories) were activated in one step with EDAC [1-ethyl-3-(3-
dimethyl-aminopropyl) carbodiimide hydrochloride] and NHS
[N-hydroxy succinimide] in 100 mM MES (2-[N-Morpholino]
ethanesulfonic acid) pH 5.5 buffer. Activated beads were washed
with 0.01 M phosphate-buffered saline pH 7.2 (PBS) and then
incubated with different amounts of OAg-AcrA. Resulting
functionalized magnetic beads were washed with quenching buffer
(35 mM glycine, 1% gelatin from cold water fish skin) and
incubated overnight at 4uC with the same buffer. Finally, OAg-
AcrA-beads were washed with storage buffer (1% gelatin from cold
Author Summary
Brucellosis is one of the most widespread zoonoses in the
world and still represents a mayor animal and human
health problem in many endemic areas. Central for early
diagnosis and appropriate treatment of the disease in
humans is to have an easy to implement, fast and accurate
diagnostic test for the disease. Currently, most of the
diagnostic tests for human brucellosis are not of simple
implementation in areas where laboratory infrastructure or
trained personnel are not available. We present here a
novel and simple diagnostic test for human brucellosis
using a glyco-engineered antigen coupled to magnetic
beads. Our results show that, with this new method, it is
possible to detect infection caused by the three main
human brucellosis agents with high sensitivity and
specificity. We additionally demonstrate that this assay
allows the selection of different cutoff points so that the
desired operating characteristics of the test in terms of
diagnostic sensitivity and specificity can be adjusted
according to the needs of the operator. We believe that
the high accuracy, low cost and simplicity of this new test
makes it an attractive diagnostic tool not only for clinics
and brucellosis reference laboratories but also for locations
with limited laboratory infrastructure and/or minimally
trained community health workers.
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water fish skin, 2.25% Tween 20, 0.01% sodium azide),
resuspended in the same buffer and stored at 4uC until use.
To perform the assay, OAg-AcrA-functionalized microbeads
were incubated with human serum samples, washed two times
with 0.01 M phosphate-buffered saline pH 7.2 containing 0.2%
Tween 20 (PBST) and bound antibodies were detected incubating
the beads with Cy5-conjugated goat anti human IgM/G
antibodies (Jackson ImmunoResearch Laboratories). After wash-
ing twice with PBST, fluorescence was determined using a plate
fluorometer (DTX 880 Multimode Detector, BeckmanCoulter).
All washes were done using a magnetic rack.
In order to determine the optimal antigen concentration,
sample and antibody dilutions and incubation times, a checker-
board titration analysis was carried out using high-, medium-, low-
positive and negative sera, and checking for strong versus low
background. Based on these analyses the optimal amount of
antigen was 2 mg per reaction, the optimal serum sample dilution
was at 1/100 and the incubation times with the sample and the
conjugate was reduced to 5 minutes at room temperature. These
parameters were used to test all the samples.
Human serum samples
A total of 488 serum samples of healthy individuals and patients
belonging to different clinical groups were analyzed (see Figure S1
and Table S3 in the supplemental material).
(i) Culture-positive brucellosis patients: patients with positive
blood cultures for Brucella abortus, Brucella melitensis or
Brucella suis (52 serum samples of 25 patients).
(ii) Culture-negative brucellosis patients: culture-negative bru-
cellosis patients with clinical diagnosis of brucellosis and
serologically-positive by Rose Bengal Test (RBT), Serum
Agglutination Test (SAT; Huddleson), Tube Agglutination
Test (TAT; Wright), TAT-2ME (2-mercaptoethanol),
Competitive ELISA (CELISA) and/or Complement Fix-
ation Test (CFT) (86 samples of 48 patients). The CELISA
was performed as indicated in [8].
(iii) Blood donors: healthy individuals with no epidemiological
evidence of brucellosis and negative agglutination tests (240
serum samples).
(iv) Patients with febrile syndrome: patients with febrile illness
whose serum samples were negative by RBT, SAT, TAT,
TAT-2ME, CELISA and CFT (34 serum samples).
(v) Healthy individuals occupational exposed to the pathogen:
research, clinical and production laboratory workers, and
cattle ranchers (30 serum samples).
(vi) Patients with other bacterial infections or with autoim-
mune pathologies: patients infected with Escherichia coli
O157:H7 (14 serum samples), Mycobacterium tuberculosis (9
serum samples), Klebsiella pneumoniae (3 serum samples),
Acinetobacter baumannii (4 serum samples), Pseudomonas
aeruginosa (1 serum sample), or Streptococcus pneumoniae (1
serum sample), or with autoimmune pathologies such as
rheumatoid arthritis, systemic lupus erythematosus or
autoimmune vasculitis (14 serum samples).
Western blotting
Non-glycosylated and glycosylated AcrA were subjected to 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) [9], and transferred to a nitrocellulose membrane with a semi-
dry membrane transfer. Immunoblotting was performed as previ-
ously described [10] with human serum samples, and mouse anti-
Brucella O-polysaccharide (M84) [11] and anti-histidine tag (Qiagen)
monoclonal antibodies. Bound antibodies were visualized using
horseradish peroxidase-conjugated goat anti-human IgG (Sigma)
secondary antibodies and enhanced chemiluminescence (Supersignal
West Pico chemiluminescent substrate detection reagents, Pierce
Chemical Co.), according to the manufacturer’s instructions.
Data analysis
Results were expressed as percentage of reactivity of the mean
Fluorescence Units (FU) of the positive control serum included in
each assay run. Percentage of reactivity was calculated as follows:
% of reactivity = (FU of the test sample/mean FU of the positive
control)6100.
Dot, receiver-operating characteristic (ROC) and Spearman’s
correlation analyses were performed using the GraphPad Prism
software (version 5.01 for Windows, San Diego California USA,
[http://www.graphpad.com]).
Results
OAg-AcrA glycoconjugate as a novel antigen for the
diagnosis of human brucellosis
An indirect immunoassay based on the detection of anti O-
polysaccharide IgG/M antibodies in serum samples was developed
using as antigen the recombinant O:9-polysaccharide-protein
conjugate (OAg-AcrA). The glycoprotein OAg-AcrA was devised
and produced using an in vivo bacterial glycosylation system, as
previously described [6], purified from periplasmic extracts by
affinity chromatography and characterized by Western blot
analysis. As shown in Figure 1A, the glycosylated form of AcrA
was recognized by the anti-histidine tag monoclonal antibody
(AcrA was expressed as an histidine tag fusion protein) and an anti-
Brucella O-antigen monoclonal antibody, while the non-glycosylat-
ed form was only detected by the anti-histidine tag antibody.
As a proof of concept and to demonstrate the feasibility of the use
of OAg-AcrA antigen for the diagnosis of human brucellosis, we
analyzed serum samples obtained from patients with culture-
confirmed brucellosis by B. abortus (bv1 and bv2), B. suis (bv1) and B.
melitensis as well as from healthy blood donors (Figure 1B). To
perform the assay, super-paramagnetic beads functionalized with
the antigen were incubated with the samples for 5 min at RT and
washes were performed using a magnetic rack without the need of
centrifugation. Then, magnetic beads were incubated with Cy5-
conjugated anti-human IgM/G antibodies (5 min at RT), washed,
and detection was performed directly by reading the fluorescence
without the need to add an additional substrate. The obtained
results demonstrate that using the recombinant glycoconjugate as
antigen it is possible to discriminate between infected patients and
non-infected individuals. Furthermore, to evaluate the specificity of
the reaction, the same sera were analyzed by Western blot against
the non-glycosylated and glycosylated forms of AcrA (Figure 1C).
Reactivity against glycosylated AcrA was observed with the serum
samples obtained from infected patients but not with the samples of
healthy blood donors, and none of the samples were reactive against
the non-glycosylated form of AcrA. These results indicate that the
detected antibody response is specifically directed towards the O-
polysaccharide moiety of the glycoconjugate.
Taken together these results demonstrate the potential of this
glyco-engineered antigen-based assay for the diagnosis of human
brucellosis caused by the three main human brucellosis pathogens.
Glycoconjugate magnetic beads-based assay validation
To validate the assay, a total of 488 serum samples obtained
from healthy individuals and patients of different clinical groups
Glycoconjugate-Beads Assay for Human Brucellosis
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were tested as indicated in Materials and Methods. The reactivity
values of these samples were outlined in a dotplot diagram as
shown in Figure 2A. The results indicate that with this assay it is
possible to clearly discriminate between culture-positive patients
(mean value 6 SD, 93.90674.78%) and culture-negative/
serologically-positive patients with clinical diagnosis of brucellosis
(55.66650.06) from blood donors (5.1961.80), healthy individuals
occupational exposed to the pathogen (8.9162.40), patients with
febrile syndrome (9.5461.76) and patients with other infectious or
autoimmune diseases (7,2562.53).
A further analysis of the results was performed classifying the
samples into two categories (Figure 2B). The non-brucellosis
category includes samples obtained from blood donors, healthy
individuals occupational exposed to the pathogen, patients with
febrile syndrome and patients with other diseases. The brucellosis
category includes samples of patients with culture-confirmed
brucellosis and culture-negative but serologically positive patients
with clinical diagnosis of brucellosis. For each category reactivity
values were arranged in increasing order and its distribution
showed a minimal overlap between categories (see inset in
Figure 1. OAg-AcrA glycoconjugate as an antigen for the diagnosis of human brucellosis. A) 10% SDS-PAGE analysis of purified non-
glycosylated (NG) and glycosylated AcrA (G) by Coomassie brilliant blue and immunoblot using anti-histidine tag and anti-Brucella O-antigen
monoclonal antibodies. B) Glycoconjugate magnetic beads-based immunoassay for detection of antibodies against the O-polysaccharide fraction of
lipopolysaccharide (LPS). Magnetic beads coated with OAg-AcrA were incubated with the indicated human serum samples. Bound antibodies were
detected using Cy5-conjugated goat anti human IgM/G antibodies.Positive and negative controls; human sera included as positive and negative
controls in each assay run. The figures in parenthesis correspond to the identification of the samples according to Tables S1 and S2. Results are
expressed as percentage of reactivity of the positive control serum. The bar graph data represents the means and standard deviation for two separate
determinations. C) Western blot analysis of the same human serum samples.
doi:10.1371/journal.pntd.0002048.g001
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Figure 2. Glycoconjugate-magnetic beads assay analysis of serum samples obtained from healthy individuals and patients of
different clinical groups. A) Dotplot of the glycoconjugate-magnetic beads assay results. Serum samples of blood culture-positive patients (52
sera), culture-negative/serologically-positive patients with clinical diagnosis of brucellosis (86 sera), blood donors (240 sera), healthy individuals
occupational-exposed to the pathogen (30 sera), patients with febrile syndrome (34 sera) and patients with other diseases (46 sera) were tested as
indicated in Materials and Methods. The mean and standard deviation for each group are indicated. B) Analysis of glycoconjugate-magnetic beads
assay results classifying the samples into two categories. Non-brucellosis category includes samples obtained from blood donors, healthy individuals
occupational-exposed to the pathogen, patients with febrile syndrome and patients with other diseases. Brucellosis category includes samples of
blood culture-positive and culture-negative/serologically-positive patients with clinical diagnosis of brucellosis. For each category reactivity values are
arrange in increasing order. The horizontal lines indicate the cutoff values calculated by ROC analysis for which maximal sensitivity (Se) or specificity
(Sp) is achieved. The inset shows a zoom of the graph part displaying the limit between categories.
doi:10.1371/journal.pntd.0002048.g002
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Figure 2B) indicating that it is possible to select different cutoff
points so that the desired operating characteristics of the test in
terms of diagnostic sensitivity and specificity can be adjusted (see
below).
To evaluate the diagnostic performance of the assay and
determine the cutoff values that concurrently optimize sensitivity
and specificity, a receiver-operating characteristic (ROC) analysis
was performed. The underlying assumption of ROC analysis is
that a diagnostic variable (e.g. glycoconjugate-magnetic beads
assay values) is used to discriminate between two mutually
exclusive states of tested individuals. At first, ROC analysis was
performed considering as negative controls only the serum samples
obtained from healthy blood-donors (240 sera). Serum samples
obtained from patients with culture-confirmed brucellosis and
culture-negative/serologically-positive patients with clinical diag-
nosis of brucellosis (138 sera) were used as positive controls. Based
on this analysis, the area under the ROC curve (AUC) for the test
was 1.000 (95% CI, 0.9999 to 1.000) and the optimum cutoff value
was 13.00% which resulted in a diagnostic sensitivity of 100%
(95% CI, 97.36 to 100) and specificity of 99.58% (95% CI, 97.70
to 99.99) with only one false positive. When a cutoff value of
14.18% was selected the sensitivity fell to 99.28% (95% CI, 96.03
to 99.98), with one false negative, and the specificity increased to
100% (95% CI, 98.47 to 100).
However, considering as negative controls only the samples of
healthy blood-donors possibly overestimates the test specificity
because patients who may have cross-reacting antibodies, such as
those with clinical suspicion of brucellosis, exposed to the pathogen
or with other diseases, are not being considered in the analysis.
Thus, a second ROC analysis was carried out including as
negative controls the serum samples obtained from all the clinical
groups previously included in the non-brucellosis category (350
sera, see Figure 2B). In this case, the AUC for the test
was 0.9997 (95% CI, 0.9993 to 1.000) indicating that the
Figure 3. Receiver-operating characteristic (ROC) analysis of glycoconjugate-magnetic beads assay results. A) ROC plot. The analysis
was carried out considering as positive controls sera of patients with culture-confirmed brucellosis and culture-negative/serologically-positive
patients with clinical diagnosis of brucellosis (138 sera), and as negative controls serum samples from blood-donors, healthy individuals occupational-
exposed to the pathogen, patients with febrile syndrome and patients with other diseases (350 sera). AUC, area under the ROC curve. Values in
parentheses indicate the 95% confidence interval. B) Plot of the diagnostic sensitivity (Se) and specificity (Sp) of the assay as a function of the cutoff
value. The dot vertical line indicates the cutoff value that concurrently optimizes Se and Sp (cutoff = 14.18%, Se = 99.28% and Sp = 99.43%). The dash
vertical lines indicate the cutoff values for which maximal Se or Sp is achieved (cutoff = 13.20%, Se = 100% and Sp = 98.57%; cutoff = 16.15%,
Se = 93.48% and Sp = 100%).
doi:10.1371/journal.pntd.0002048.g003
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glycoconjugate-magnetic beads assay is highly accurate for the
diagnosis of human brucellosis (Figure 3A). Furthermore, a plot of
sensitivity and specificity as a function of the cutoff values allowed
us to determine the cutoff value (14.18%) that maximizes
sensitivity and specificity and select two different cutoff values
(13.20 and 16.15%) for definition of intermediate test results (test
results that are considered non-negative and non-positive)
(Figure 3B). As shown in Table 1, the optimum cutoff value of
14.18% resulted in a diagnostic sensitivity and specificity of
99.28% (95% CI, 96.03 to 99.98) and 99.43 (95% CI, 97.95 to
99.93), respectively, with one false-negative and two false-positive
results. The cutoff value of 13.20% resulted in a diagnostic
sensitivity of 100% (95% CI, 97.36 to 100), a diagnostic specificity
of 98.57% (95% CI,96.70 to 99.53), with 5 false positives, and a
negative predictive value of 100%. A cutoff value of 16.15%
resulted in a test sensitivity of 93.48% (95% CI, 87.98 to 96.97)
with 9 false negatives, a test specificity of 100% (95% CI, 98.91 to
100) and a positive predictive value of 100%.
Fifty-two samples of 25 patients with blood culture-confirmed
brucellosis were tested. In 6 patients the isolated strain was B. suis,
in 8 cases B. abortus and in 11 cases B. melitensis. In one patient, who
had a right knee bursitis, the bacterium was isolated from the
synovial fluid. Interestingly, the serum and synovial fluid samples
were positive by the glycoconjugate-beads assay suggesting that
our assay could be used to diagnose the disease using different
types of samples. In this group the sensitivity of the glycoconju-
gate-beads assay (cutoff .13.20%) was 100% demonstrating that
this assay can be used to diagnose brucellosis caused by the three
main human brucellosis pathogens. When considering all the
positive samples obtained from culture-positive and culture-
negative brucellosis patients the diagnostic sensitivity of the
glycoconjugate-beads assay and CELISA was significantly higher
than the sensitivity of RBT, SAT, TAT and CFT (Table 2).
Finally, we analyzed samples of nine brucellosis patients who
received antibiotic therapy. The serological follow-up performed
with serial serum samples obtained at admission and 1, 2, or more
months after treatment showed that the glycoconjugate-beads
assay values correlated very well with CELISA and CFT results
(Table 3, and Tables S1 and S2 in the supplemental material).
When a Spearman’s correlation analysis was performed consid-
ering all the positive reference samples (138 sera), the correlation
coefficient between the glycoconjugate-beads assay and CELISA
was 0.7771 (P,0.0001, 95% CI 0.6945 to 0.8394), between our
assay and CFT was 0.8155 (P,0.0001, 95% CI 0.7441 to 0.8684),
while the correlation between CELISA and CFT fell to 0.7254
(P,0.0001, 95% CI 0.6264 to 0.8014).
Table 2. Sensitivity values of the different serological testsa.
Number of
samples TEST (cutoff) TP FN Se (%)
138 RBT 84 54 60.87
138 SAT ($100) 70 68 50.72
138 SAT ($25) 121 17 87.68
138 TAT($100) 64 74 46.37
138 TAT($25) 123 15 89.13
127 CELISA (.28%I)b 125 2 98.43
125 CFT ($5) 95 30 76.00
138 GBAc (.13.20%) 138 0 100
138 GBAc (.16.15%) 129 9 93.48
aThe analysis was performed considering as positive reference controls sera
obtained from patients with culture-confirmed brucellosis (52 sera) and from
culture-negative/serologically-positive patients with clinical diagnosis of
brucellosis (86 sera).
b%I, percentage of inhibition.
cGBA, glycoconjugate-beads assay.
TP, true positives; FN, false negatives; Se, sensitivity (TP/TP+FN)6100.
doi:10.1371/journal.pntd.0002048.t002
Table 1. Sensitivity, specificity, performance index, and positive and negative predictive values of the test calculated for different
cutoff valuesa.
Cutoff (%) Se (%)b Sp (%)b PIc PPV (%)d NPV (%)d TP TN FP FN
.13.20 100e (97.36–100) 98.57 (96.70–99.53) 198.57 96.50 100 138 345 5 0
.13.45 99.28 (96.03–99.98) 98.57 (96.70–99.53) 197.85 96.48 99.71 137 345 5 1
.13.80 99.28 (96.03–99.98) 98.86 (97.10–99.69) 198.14 97.16 99.71 137 346 4 1
.14.08 99.28 (96.03–99.98) 99.14 (97.52–99.82) 198.42 97.86 99.71 137 347 3 1
.14.18 99.28 (96.03–99.98) 99.43 (97.95–99.93) 198.71 98.56 99.71 137 348 2 1
.14.24 98.55 (94.86–99.82) 99.43 (97.95–99.93) 197.98 98.55 99.43 136 348 2 2
.14.39 98.55 (94.86–99.82) 99.71 (98.42–99.99) 198.26 99.27 99.43 136 349 1 2
.14.75 97.83 (93.78–99.55) 99.71 (98.42–99.99) 197.54 99.26 99.15 135 349 1 3
.15.10 97.10 (92.74–99.20) 99.71 (98.42–99.99) 196.81 99.26 98.87 134 349 1 4
.15.25 96.38 (91.75–98.81) 99.71 (98.42–99.99) 196.09 99.25 98.59 133 349 1 5
.15.40 95.65 (90.78–98.39) 99.71 (98.42–99.99) 195.36 99.25 98.31 132 349 1 6
.15.55 94.20 (88.90–97.46) 99.71 (98.42–99.99) 193.91 99.24 97.76 130 349 1 8
.16.15 93.48 (87.98–96.97) 100 (98.95–100) 193.48 100 97.49 129 350 0 9
aThe analysis was performed using 138 sera as positive-controls and 350 sera as negative-controls.
bSe, sensitivity (TP/TP+FN)6100; Sp, specificity (TN/TN+FP)6100. Values in parentheses indicate the 95% confidence interval. TP, true positives; TN, true negatives; FP,
false positives; FN, false negatives.
cPI, performance index calculated as the sum of the sensitivity and specificity values.
dPPV, positive predictive value (TP/TP+FP)6100; NPV, negative predictive value (TN/TN+FN)6100.
eMaximum values for Se, Sp, PI, PPV and NPV are indicated in bold.
doi:10.1371/journal.pntd.0002048.t001
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Table 3. Serological follow-up of patients treated with antibiotic therapy.
Patient N6 Samplesa Blood Culture Glycoconjugate-beads assay (%)b CELISA (%I)c FCd
28 a(0) Negative 155.1 81 320
b(2) 85.6 66 80
c(4) 50.7 48 40
d(7) 26.8 46 40
36 a(0) Negative 113.4 74 160
b(7) 41.5 56 20
c(11) 51.1 45 5
d(16) 17.9 42 5
e(19) 40.2 45 5
f(23) 35.6 40 5
1 a(0) B. suis bv 1 79.3 76 1280
b(2) 133.6 76 640
c(5) 255.9 94 1280
d(9) 296.9 91 640
e(13) 223.3 92 320
f(17) 201.1 81 160
g(20) 137.0 55 80
h(23) 151.9 60 80
i(26) 111.8 73 40
j(29) 122.4 75 40
3 a(0) B. suis bv 1 105.9 63 320
b(13) 302.3 91 160
c(17) 226.9 89 160
d(20) 232.1 85 80
e(30) 111.7 72 20
f(32) 126.8 71 20
6 a(0) B. abortus bv 1 102.2 64 320
b(3) 65.6 61 80
c(8) 58.5 48 40
7 a(0) B. suis bv 1 121.6 64 160
b(2) 167.4 74 320
c(6) 74.6 52 40
10 a(0) B. abortus bv 2 69.9 65 10
b(5) 27.0 45 5
c(10) 22.3 43 NEG
d(12) 15.5 30 NEG
37 a(0) Negative 129.2 68 80
b(2) 77.1 48 80
c(3) 82.6 52 40
d(6) 72.8 62 20
e(10) 47.0 60 20
f(32) 24.5 49 10
39 a(0) Negative 158.8 88 160
b(3) 237.5 92 320
c(4) 249.3 93 640
d(6) 151.2 92 320
e(8) 125.9 91 80
f(10) 80.7 88 80
g(13) 68.9 82 20
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Discussion
Timely and accurate diagnosis of human brucellosis continues
to challenge clinicians due to its non-specific clinical features, the
slow growth rate of Brucella spp. in blood cultures, and the
complexity of its serodiagnosis [2]. Since the humoral immune
response to ‘‘smooth’’ brucellae is dominated by antibodies to the O-
polysaccharide section of Brucella sLPS and because Yersinia
enterocolitica O:9 and Brucella abortus share an almost identical O-
polysaccharide structure, we explored the application of the
recombinant Y. enterocolitica O:9-polysaccharide-protein conjugate
(OAg-AcrA) in the diagnostics of human brucellosis.
In the present work we described the development, optimization
and validation of an indirect immunoassay to detect antibodies
against ‘‘smooth’’ Brucella spp. using the recombinant glycoconju-
gate OAg-AcrA antigen coupled to magnetic beads. The assay was
validated using a panel of characterized serum samples obtained
from healthy individuals and patients of different clinical groups
including not only patients with brucellosis but also patients with
febrile syndrome and symptoms compatible with brucellosis as well
as patients with other infections or autoimmune diseases, who may
have cross-reacting antibodies. The obtained results allowed us to
validate the assay and select different cutoff values taking into
account the actual epidemiological situation of the disease. We
demonstrated that using the glycoconjugate-beads assay it is
possible to clearly discriminate between infected and non-infected
individuals and that this assay is efficient to detect infections
caused by the three main human brucellosis pathogens: B. abortus,
B. melitensis and B. suis. We also confirmed by immunoblot that the
detected antibody response in positive serum samples is specifically
directed towards the O-polysaccharide moiety of the glycoconju-
gate. To evaluate the performance of the assay a receiver-
operating characteristic (ROC) analysis was performed. ROC
analysis provides a precise and valid measure of diagnostic
accuracy and assesses the diagnostic performance of the system in
terms of the true-positive rate (sensitivity) and false-positive rate (1-
specificity) for each possible cutoff value of the test [12,13]. The
area under the ROC curve (AUC) is a global summary statistic of
diagnostic accuracy and one could distinguish between non-
informative (AUC=0.5), less accurate (0.5,AUC,0.7), moder-
ately accurate (0.7,AUC,0.9), highly accurate (0.9,AUC,1)
and perfect tests (AUC=1) [13]. For our assay, the AUC was
0.9997 indicating that the glycoconjugate-beads assay is a highly
accurate test to diagnose human brucellosis. The cutoff value that
concurrently optimizes sensitivity and specificity was determined
to be 14.18%, which resulted in a diagnostic sensitivity and
specificity of 99.28% and 99.43%, respectively. A cutoff value of
13.20% gave a diagnostic sensitivity of 100% and a diagnostic
specificity of 98.571%, and a cutoff value of 16.15% resulted in a
test sensitivity of 93.48% and a test specificity of 100%. Based on
this analysis, we propose the following criteria for diagnosing
human brucellosis; samples with reactivity values less or equal than
13.20% are considered non-reactive, samples with reactivity values
higher than 16.15% are considered reactive while samples with
values between 13.20 and 16.15% are indeterminate (see Table 1).
In this latter case, the result should be confirmed repeating the test
two or three weeks later or using another diagnostic method.
Considering a cutoff value of 13.20% the diagnostic sensitivity of
the glycoconjugate-beads assay was similar to that of CELISA but
significantly higher than the sensitivity of the other serological tests
considered in this study; furthermore, our test results correlated
very well with CELISA and CFT results.
OAg-AcrA was produced in Y. enterocolitica O:9 cells co-
expressing the N-linked protein glycosylation OTase PglB and
the protein acceptor AcrA of Campylobacter jejuni [6]. Introduction
of PglB and AcrA in Y. enterocolitica O:9 resulted in the transfer of
the N-formylperosamine O-polysaccharide from its lipid carrier to
AcrA and the resulting glycoprotein was purified from the
periplasm of the bacteria by affinity chromatography. Most of
the diagnostic methods currently used for human serological
testing use as antigen whole ‘‘smooth’’ Brucella cells or bacterial
extracts containing high concentrations of sLPS [4]. In these cases,
level-3 biosafety facilities (BSL-3) are required for culturing Brucella
and production of the antigens. Instead, large quantities of the
recombinant glycoconjugate OAg-AcrA antigen can be produced
and simply purified from fermentations of Y. enterocolitica O:9 (Y.
enterocolitica O:9 is a biosafety level-2 organism that is easily
manipulated and cultured) without the need for culturing Brucella,
which results in reduced costs and a safer production process. This
is relevant considering that brucellosis constitutes one of the most
common infections acquired in antigen/vaccine-manufacturing
plants and in research and clinical diagnostic laboratories
[14,15,16,17]. Furthermore, the glycoengineering technology used
in this study to produce the antigen eliminates the need to purify
LPS and no chemical treatments are required for isolation of the
O-polysaccharide from LPS. Finally, no chemical crosslinking of
the carbohydrate to the protein is required allowing to produce
conjugates with a defined and reproducible sugar pattern since the
glycosylation process and the length of the O-polysaccharide are
controlled in vivo. Therefore, this system may enable the
production of homogeneous and standardized batches of antigen
which may have, in the future, important implications for the
diagnosis of brucellosis because until now there is no standardized
reference antigen, and it is well known that the source of the
antigen used can greatly influence test results.
B. abortus O-polysaccharide contains both A (a-1,2-linked
homopolymer of N-formylperosamine) and M (pentasaccharide
with four a-1,2 and one a-1,3-linked polymers of the same sugar)
epitopes. Y. enterocolitica O:9 O-polysaccharide is comprised solely
of a-1,2-linked N-formylperosamine, B. abortus has ,98% A
epitope, B. suis has a unique 1:7 ratio of a1,3- a1,2 linked polymer,
whereas B. melitensis has only the M epitope of the pentasaccharide
Table 3. Cont.
Patient N6 Samplesa Blood Culture Glycoconjugate-beads assay (%)b CELISA (%I)c FCd
h(20) 41.1 75 5
i(31) 25.4 65 5
aThe letters indicate consecutive serum samples. The numbers in parenthesis indicate the months at which the samples were taken after admission.
bResults are expressed as percentage of reactivity of the control positive serum. Cutoff .13.2%.
cCutoff .28%I.
dResults are shown as titers. Cutoff $5.
doi:10.1371/journal.pntd.0002048.t003
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repeating unit [18,19,20]. These O-polysaccharide structural
similarities may explain why the OAg-AcrA antigen was reactive
towards serum samples obtained from patients with culture-
confirmed brucellosis by B. abortus, B. suis or B. melitensis. On the
other hand, it is well known that the structural similarity between
the O-chains of Yersinia enterocolitica O:9, smooth Brucella spp. and
various other clinically relevant bacteria, such us Salmonella urbana
group N, Vibrio cholerae, Francisella tularensis, Escherichia coli O:157
and Stenotrophomonas maltophilia, could lead to cross-reactivity
increasing the possibility of false-positive results [21]. In this
regard, 14 serum samples of patients with Uremic Hemolytic
Syndrome caused by Escherichia coli O157:H7 (see the group of
patients with other diseases) were analyzed and no cross-reaction
was observed. However, due to the possibility of cross-reactions
with the bacteria mentioned above, not only the serological tests
results but also the clinical and epidemiological context must be
considered to confirm the diagnosis. Finally, the whole bacteria
and most of the LPS-based assays currently used to diagnose
brucellosis not only suffers from false-positive results due to these
O-chains structural similarities but also due to the presence of
cross-reactive antibodies against the common core and lipid A
antigens. Instead, the glycoconjugate-beads assay may be more
specific than these assays since it uses as antigen only the O-
polysaccharide fraction of the LPS.
Laboratory testing is essential for diagnosing brucellosis and
access to appropriate diagnostic tools is a critical component for
early diagnosis and patient management. However, most currently
available diagnostic tests may be difficult to implement in
resource-poor countries or regions where brucellosis is endemic.
An exception are the Rose Bengal Test [22] and the immuno-
chromatographic brucella IgM/IgG Lateral Flow Assay [23]
which are simple and rapid methods proposed to be used as POC
tests, albeit the fact the interpretation of RBT results are largely
subjective [2,4]. In addition, and especially in developing
countries, not all the patients have access to medical services
and the local health-care centers may have limited infrastructure
and staff might not be able to make or confirm the diagnosis.
Presently, 72% of the population in Africa, 42% in Asia and 10%
in America only have access to health-care settings with minimal
infrastructure or no infrastructure at all [24,25]. Due to the high
diagnostic accuracy, the low cost in terms of production of the
antigen, reduced assay time (no more than 15 min), simplicity (no
centrifugation and agitation needed and no additional substrate
required for detection by fluorescence reading) as well as the
availability of portable fluorescence readers, the glycoconjugate-
magnetic beads assay may have a great potential as a Point-Of-
Care (POC) test for human brucellosis. Therefore, the new
glycoconjugate-magnetic beads assay could be a useful diagnostic
tool not only for brucellosis reference laboratories or clinics but
also for locations with limited laboratory infrastructure and/or
minimally trained community health workers. Future work will be
needed to validate the assay in regions or countries with lower or
higher incidence of brucellosis than in Argentina.
Here, we have demonstrated that the glycoconjugate-beads
assay has an excellent performance for the diagnosis of human
brucellosis and have validated for the first time a bacterial
recombinant glycoprotein as an antigen for the diagnosis of an
infectious disease. Further work will be required to validate the
recombinant glycoconjugate antigen OAg-AcrA for the diagnosis
of animal brucellosis caused by ‘‘smooth’’ Brucella spp. strains, as
well as to exploit the bacterial glyco-engineering technology to
design and produce a panel of glycoconjugates for diagnostics of
other relevant human and veterinary infectious diseases.
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